CSL Limited
Labor and Coalition in lockstep as Trump threatens to pull pharma tariffs forward
Donald Trump has announced plans to impose sky-high tariffs on pharmaceuticals, Australia’s third-largest export to the US.
- Nick Newling
Latest
- Opinion
- Medicine
The Kennedy curse is hitting Australia’s vaccine giant
Having a renowned anti-vaxxer in charge of America’s health system can’t be healthy for a company that wants to grow its vaccine business.
- Elizabeth Knight
- Exclusive
- Coronavirus pandemic
How the Morrison government passed over an Australian company for a US pharmaceutical giant
Australia’s audit office will probe the Morrison government’s $2 billion deal with US pharmaceutical giant Moderna to set up vaccine manufacturing in Australia.
- Paul Sakkal and Liam Mannix
- Exclusive
- Funding
The hundreds of millions in tax incentives for Australian start-ups that went south
The R&D tax offset has served as a life raft for some of Australia’s most prominent technology start-ups, though in some cases it wasn’t enough.
- David Swan
- Updated
- World markets
ASX slides despite Wall Street rebound
Rate-sensitive sectors including consumer stocks dragged the local sharemarket lower, despite a US equities rebound overnight following its steep sell-off.
- Millie Muroi
Failed drug trial overshadows CSL’s bumper profits
Investors have punished the company’s share price for the second day in a row – despite it booking revenue of $12.3 billion for the half-year to December 31.
- David Swan
Health behemoth CSL sheds $7b in value after heart drug fails trial
Shares in the blood plasma treatments maker were trading nearly 5 per cent lower following the results.
- Millie Muroi
- Analysis
- Active investing
Nine stock picks from some of Australia’s biggest fund managers
From garbage collection to race car manufacturing, nine fund managers at some of Australia’s largest investment firms have given their best stock picks.
It’s throwing its weight around, but can Ozempic reshape our economy?
From health to fast food, investors are starting to question which companies will be slimmed thanks to weight-loss drugs.
- Emma Koehn and Colin Kruger
Our biggest healthcare company says it isn’t scared of Ozempic
CSL has outlined its growth strategy to investors and played down concerns about weight-loss drugs’ impact on some of its key products.
- Emma Koehn
Original URL: https://www.brisbanetimes.com.au/topic/csl-g9